Northern Trust’s Bellicum Pharmaceuticals, Inc. BLCM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q2 | – | Sell |
-10,981
| Closed | -$3.62K | – | 4633 |
|
|
2023
Q1 | $3.62K | Hold |
10,981
| – | – | ﹤0.01% | 4569 |
|
|
2022
Q4 | $7.91K | Hold |
10,981
| – | – | ﹤0.01% | 4595 |
|
|
2022
Q3 | $13K | Hold |
10,981
| – | – | ﹤0.01% | 4615 |
|
|
2022
Q2 | $13K | Hold |
10,981
| – | – | ﹤0.01% | 4675 |
|
|
2022
Q1 | $24K | Hold |
10,981
| – | – | ﹤0.01% | 4653 |
|
|
2021
Q4 | $16K | Hold |
10,981
| – | – | ﹤0.01% | 4727 |
|
|
2021
Q3 | $32K | Hold |
10,981
| – | – | ﹤0.01% | 4585 |
|
|
2021
Q2 | $36K | Hold |
10,981
| – | – | ﹤0.01% | 4517 |
|
|
2021
Q1 | $41K | Hold |
10,981
| – | – | ﹤0.01% | 4399 |
|
|
2020
Q4 | $39K | Buy |
+10,981
| New | +$46.3K | ﹤0.01% | 4261 |
|
|
2020
Q1 | – | Sell |
-9,544
| Closed | -$123K | – | 4284 |
|
|
2019
Q4 | $123K | Sell |
9,544
-2
| -0% | -$18 | ﹤0.01% | 3897 |
|
|
2019
Q3 | $100K | Sell |
9,546
-32,425
| -77% | -$424K | ﹤0.01% | 3927 |
|
|
2019
Q2 | $714K | Sell |
41,971
-4,901
| -10% | -$133K | ﹤0.01% | 3457 |
|
|
2019
Q1 | $1.58M | Buy |
46,872
+166
| +0.4% | +$5.55K | ﹤0.01% | 3202 |
|
|
2018
Q4 | $1.36M | Sell |
46,706
-2,133
| -4% | -$94.6K | ﹤0.01% | 3253 |
|
|
2018
Q3 | $3.01M | Buy |
48,839
+2,144
| +5% | +$145K | ﹤0.01% | 2984 |
|
|
2018
Q2 | $3.44M | Buy |
46,695
+15,375
| +49% | +$1.2M | ﹤0.01% | 2904 |
|
|
2018
Q1 | $2.05M | Sell |
31,320
-2,549
| -8% | -$192K | ﹤0.01% | 3085 |
|
|
2017
Q4 | $2.85M | Sell |
33,869
-509
| -1% | -$49.9K | ﹤0.01% | 2928 |
|
|
2017
Q3 | $3.97M | Buy |
34,378
+222
| +0.6% | +$23.4K | ﹤0.01% | 2777 |
|
|
2017
Q2 | $3.99M | Buy |
34,156
+7,776
| +29% | +$965K | ﹤0.01% | 2758 |
|
|
2017
Q1 | $3.25M | Buy |
26,380
+156
| +0.6% | +$20.4K | ﹤0.01% | 2821 |
|
|
2016
Q4 | $3.57M | Buy |
26,224
+947
| +4% | +$168K | ﹤0.01% | 2765 |
|
|
2016
Q3 | $5.03M | Buy |
25,277
+2,212
| +10% | +$381K | ﹤0.01% | 2514 |
|
|
2016
Q2 | $2.99M | Buy |
23,065
+12,974
| +129% | +$1.44M | ﹤0.01% | 2809 |
|
|
2016
Q1 | $943K | Buy |
10,091
+2
| +0% | +$218 | ﹤0.01% | 3276 |
|
|
2015
Q4 | $2.04M | Buy |
10,089
+442
| +5% | +$79.1K | ﹤0.01% | 3054 |
|
|
2015
Q3 | $1.4M | Buy |
9,647
+1,017
| +12% | +$187K | ﹤0.01% | 3217 |
|
|
2015
Q2 | $1.84M | Buy |
8,630
+6,486
| +303% | +$1.59M | ﹤0.01% | 3102 |
|
|
2015
Q1 | $496K | Buy |
+2,144
| New | +$519K | ﹤0.01% | 3615 |
|
Other funds holding BLCM
BC
BRWA
TCM
PGAM
Northern Trust's BLCM Position: Q2 2023 in Review
Northern Trust sold out of Bellicum Pharmaceuticals, Inc. (BLCM) in Q2 2023, closing a stake of 10,981 shares — an estimated $3.62K sold.
Northern Trust first reported a position in BLCM in Q1 2015 and held it in 30 quarters. The position peaked at $5.03M in Q3 2016. 4 funds tracked by Wall St. Rank hold BLCM as of Q2 2023.
- Northern Trust reported no remaining Bellicum Pharmaceuticals, Inc. position as of Q2 2023 after selling out during the quarter.
- Northern Trust sold 10,981 Bellicum Pharmaceuticals, Inc. shares in Q2 2023, an estimated $3.62K.
- Northern Trust first reported a position in Bellicum Pharmaceuticals, Inc. in Q1 2015 and held it in 30 quarters.
- Northern Trust's Bellicum Pharmaceuticals, Inc. position peaked at $5.03M in Q3 2016.
- 4 funds tracked by Wall St. Rank held Bellicum Pharmaceuticals, Inc. as of Q2 2023.
Based on Northern Trust's 13F filing for Q2 2023, filed 11 Aug 2023.